EDH AND TERTHERA ENTERS INTO EXCLUSIVE DISTRIBUTION AGREEMENT FOR TERBIUM-161
Agreement will enable a swift introduction of Tb-161 into Türkiye, Bulgaria and Azerbaijan, enabling the application of a novel radiopharmaceutical for cancer healthcare. BREDA, 17 October 2023 – EDH Nükleer Tıp & Sağlık Hizmetleri (“EDH”), a trailblazer in the domain of radiopharmacy and nuclear medicine,and TerThera BV are pleased to announce the signing of an exclusive distribution agreement for the regions Türkiye, Bulgaria and Azerbaijan. Terbium-161, a carrier free lanthanide produced by neutron activation, is a highly promising radionuclide for